SMN-C3 is an orally active SMN2 splicing modulator and has the potential to treat spinal muscular atrophy (SMA). SMN-C3 is in phase I clinical trials co-developed by Roche and PTC Therapeutics for the treatment of spinal muscular atrophy.
武漢永璨生物科技有限公司
聯(lián)系商家時(shí)請(qǐng)?zhí)峒癱hemicalbook,有助于交易順利完成!
武漢永璨生物